Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.43 |
| ▸ | FNTB | P49356 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6633491 | 0.90 | USP30 (0.43) | FNTAFNTBALDH1A1MAPTKDM4E | |
| SCHEMBL3501091 | 0.90 | FNTA (0.42) | FNTAFNTBALDH1A1KDM4EHPGD | |
| SCHEMBL3502090 | 0.84 | FNTA (0.48) | FNTAFNTBALDH1A1KDM4EHPGD | |
| SCHEMBL6637954 | 0.81 | FNTA (0.46) | FNTAFNTB | |
| SCHEMBL6632164 | 0.81 | NPC1 (0.39) | FNTAFNTBRAB9A | |
| SCHEMBL3502066 | 0.79 | FNTA (0.46) | FNTAFNTB | |
| SCHEMBL3498412 | 0.79 | FNTA (0.41) | FNTAFNTBALDH1A1MAPTKDM4E | |
| SCHEMBL3501016 | 0.78 | FNTA (0.46) | FNTAFNTB | |
| SCHEMBL3499535 | 0.75 | FNTA (0.75) | FNTAFNTBALDH1A1MAPTKDM4E | |
| SCHEMBL6634720 | 0.74 | FNTA (0.40) | FNTAFNTBALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005089515-A9 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2006-01-26 | — | — | WO | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885ALDH1A1 2770/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885ALDH1A1 2753/4885 |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885ALDH1A1 2770/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885ALDH1A1 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.